Marlena Broncel, Iwona Marczyk, Joanna Sikora, Julita Chojnowska-Jezierska

Wpływ terapii atorwastatyn na stężenie homocysteiny, Lp(a) i fibrynogenu u pacjentów z hiperlipidemi typu II
2006-01-15

Influence of therapy with atorvastatin on homoicysteine, Lp (a) and fibrinogen blood level in patients with type 2 hyperlipidemia. Homocysteine, lipoprotein a [Lp (a)] and fibrinogen (Fb) are independent risk factors of atherosclerosis. The introduction of statins to hyperlipidemia treatment was great achievement. Despite of many well documented pleiotropic effects of statins their impact on these parameters is still controversial. The aim of the study was evaluation of atorvastatin influence on homocysteine, Lp (a), Fb concentrations in patients (pts) with hyperlipidemia (hlp) type II. The study comprised 48 pts, including 26 pts with hlp type II without concomitant chronic diseases and 22 healthy volunteers. After 8 weeks of active treatment the following parameters were determined: TC, HDL-C, TG (by enzymatic method using BioMerieux tests); LDL-C was calculated from the Friedewald formula, homocysteine and Lp (a)- immunoenzymatic method, Fb-Claussía method. Atorvastatin therapy significant decreased Lp (a) and homocysteine concentration and increased Fb level.